The COVID-19 vaccine and the flu shot are two separate vaccines. No approved flu shot on the market today contains a COVID-19 component, and no approved COVID-19 vaccine contains an influenza component. They are manufactured independently, packaged in different vials, and target different viruses. That said, the two vaccines can be given during the same appointment, and researchers are actively working on a single-shot combination that would cover both viruses in one injection. The distinction between getting two shots at once and getting one combined shot matters, and it is a source of real confusion.
Why the Confusion Exists
Several things have blurred the line between “given together” and “combined into one.” Pharmacies and clinics frequently offer both the flu shot and the COVID-19 booster during the same visit, especially in the fall. You might walk in, roll up both sleeves, and walk out with a bandage on each arm. From the patient’s perspective, it can feel like one event. Add to that the steady stream of headlines about combination flu-COVID vaccines in development, and it is easy to see how someone could wonder whether the two have already been merged.
They have not. As of now, every flu shot you receive contains only influenza antigens, and every COVID-19 vaccine contains only SARS-CoV-2 components. If you received both at the same pharmacy visit, you got two distinct injections, each drawn from its own vial.
Getting Both Shots at the Same Visit
Health authorities have been clear that receiving both vaccines on the same day is safe and practical. The CDC states that people can get a flu vaccine and a COVID-19 vaccine at the same visit if they are eligible and the timing for each vaccine is appropriate.1Centers for Disease Control and Prevention. Getting a Flu Vaccine and other Recommended Vaccines at the Same Time This is standard practice in vaccination broadly: pediatric visits have long included multiple shots on the same day, and the principle extends to adult immunizations.
The practical advantage is obvious. Bundling two vaccines into one visit means fewer trips to the pharmacy or clinic, which tends to increase the number of people who actually get both. If you had to schedule one appointment for flu and a separate appointment for COVID, many people would skip the second trip entirely. Convenience is one of the strongest predictors of vaccination uptake, so co-administration has become a deliberate public health strategy each fall.
When both are given during the same visit, they are typically administered in different arms. This is not strictly required, but it makes it easier to tell which injection site is responsible if you experience soreness or swelling afterward. Your provider will usually offer one in each deltoid.
Safety of Receiving Both at Once
A reasonable worry is that giving two vaccines simultaneously might overwhelm the immune system or cause worse side effects than either shot alone. Researchers have looked into this directly. A systematic review of clinical studies on coadministration of seasonal influenza and COVID-19 vaccines found no safety concerns and no immune interference, regardless of which specific influenza or COVID-19 vaccines were used and regardless of age group.2Taylor & Francis Online. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies
That finding held across different vaccine platforms and across both younger and older adults. The immune response to each vaccine was not blunted by the presence of the other. Side effects like arm soreness, fatigue, and low-grade fever occurred at similar rates whether the vaccines were given together or separately. In short, your body handles two shots at once about the same way it handles each one individually.
This is consistent with how the immune system actually works. Your body encounters thousands of foreign proteins every day through food, air, and normal contact with the environment. Two additional vaccine antigens on the same afternoon do not represent a meaningful extra burden. The immune system processes them in parallel, not in a queue.
The Combination Vaccine Under Development
While co-administration means two separate shots in one visit, a true combination vaccine would merge the flu and COVID-19 components into a single injection. Several pharmaceutical companies are developing exactly that, and the concept has reached the clinical trial stage. One investigational vaccine uses mRNA technology to encode antigens for both seasonal influenza strains and SARS-CoV-2 in a single formulation, and it has been studied in adults 50 years and older for both immune response and safety.3PubMed Central. Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years
The appeal of a single-shot approach is straightforward: one needle stick instead of two, one appointment instead of a potential scheduling conflict, and one product for pharmacies to stock and administer. For older adults, who are the primary target population for both vaccines, reducing friction could meaningfully increase coverage. And from a manufacturing standpoint, producing one vial instead of two could simplify supply chains.
That said, a combination vaccine has to clear a high bar before it reaches the market. Regulators require that each component of a combination vaccine performs as well as it would if given on its own. The FDA’s guidance for evaluating combination vaccines specifies that clinical studies must demonstrate that the immune response to each component is not inferior to the response from the individual vaccines given separately.4FDA. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies The safety profile also has to be comparable, meaning the combination cannot cause more frequent or more severe reactions than the individual shots. Meeting both of these requirements simultaneously is why combination vaccines take time to develop even when the individual components already exist and are well understood.
No combination flu-COVID vaccine has received FDA approval or emergency use authorization as of this writing. The trials are ongoing, and the timeline for potential approval depends on the data those trials produce. If the results hold up, a single-shot option could become available within the next few years, but it is not something you can get today.
What People Actually Want
Interestingly, researchers have already started asking whether people would choose a combination shot if it existed. A survey of about 600 U.S. consumers and roughly 300 healthcare professionals assessed preferences for a single-shot combination flu-plus-COVID vaccine versus the two standalone vaccines.5Taylor & Francis Online. US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines The study explored how both groups felt about convenience, perceived effectiveness, and willingness to receive a combination product.
The fact that this kind of preference research is happening alongside the clinical trials reflects how seriously manufacturers and public health planners are taking the combination approach. If a product clears the regulatory hurdles but nobody wants it, the public health benefit evaporates. Understanding demand in advance helps companies decide how much manufacturing capacity to build and helps clinics prepare for how they will offer the product.
For many people, the appeal comes down to needle aversion and time. Getting one shot instead of two in a single visit is a real quality-of-life improvement, even if the medical difference is negligible. For parents managing their own vaccinations alongside their children’s schedules, or for older adults with mobility challenges, reducing the number of injections has practical value beyond symbolism.
Why mRNA Technology Makes This Possible Now
The reason combination flu-COVID vaccines are suddenly a realistic prospect has a lot to do with the mRNA platform that became famous during the pandemic. Traditional flu vaccines are manufactured using egg-based or cell-based methods that take months to produce and are specific to influenza. Traditional COVID vaccines used different platforms entirely. Merging two fundamentally different manufacturing processes into one product would have been a logistical nightmare.
mRNA vaccines work differently. The core technology is the same regardless of the target virus: you encode the genetic instructions for the proteins you want the immune system to recognize, wrap those instructions in a lipid nanoparticle, and inject. To make a combination vaccine, you include mRNA sequences for both influenza and SARS-CoV-2 proteins in the same formulation. The manufacturing process does not change in a fundamental way; you are adding more instructions to the same delivery vehicle.
This flexibility is why some companies are not stopping at two viruses. There is active research into combination vaccines that could cover flu, COVID-19, and RSV (respiratory syncytial virus) in a single shot. For older adults, who are at elevated risk from all three respiratory viruses, a single annual injection covering all of them would be a significant advance. But each additional component adds complexity to the clinical trials, because regulators need to see that every component works properly in the presence of every other component.
How Combination Vaccines Get Approved
The regulatory pathway for combination vaccines is more demanding than many people realize. It is not enough to show that two vaccines are individually safe and effective and then staple them together. The FDA requires dedicated clinical trials comparing the combination product head-to-head against the individual vaccines. Specifically, the immune response to each component in the combination must be shown to be non-inferior to the response from the standalone version.4FDA. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies
This matters because combining antigens in a single formulation can sometimes cause interference. One component might trigger such a strong immune response that it partially suppresses the response to another component. Or the lipid nanoparticle delivery system might behave differently when carrying a larger payload. These are the kinds of things that only show up in carefully designed trials, which is why the regulatory process cannot be shortcut even when the individual components are already approved.
The safety evaluation is equally rigorous. Regulators want to see that the combination does not produce more frequent or more severe adverse reactions than the individual vaccines. Side effects from two vaccine components in one injection could theoretically be additive, meaning you get the soreness and fatigue of both at once rather than spreading them across two arms. Clinical trials track this carefully, comparing local reactions at the injection site and systemic symptoms like fever and body aches.
Common Misconceptions Worth Clearing Up
One persistent myth is that getting a flu shot could somehow give you COVID-19, or that the flu shot has been “secretly” updated to include COVID components. Neither is true. Flu vaccines go through their own annual reformulation process, in which the World Health Organization recommends which influenza strains to include based on global surveillance data. That process is entirely separate from COVID-19 vaccine development. The ingredients in your flu shot are publicly listed on the package insert, and no COVID-19 antigen appears on any approved flu vaccine’s label.
Another misconception is that if you got both vaccines at the same visit and then felt unwell, the combination must have been dangerous. Feeling tired or achy after vaccination is a normal sign that your immune system is responding. The systematic review data show that side effects from co-administration are not meaningfully different from what you would expect from either vaccine alone.2Taylor & Francis Online. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies You might notice symptoms from two injection sites instead of one, but the overall experience is comparable.
A subtler confusion involves the difference between “coadministration” and “combination.” In medical language, coadministration means giving two separate products at the same visit. A combination vaccine means a single product containing multiple components. These are clinically and legally distinct. When your pharmacist offers you the flu shot and the COVID booster on the same day, that is coadministration. A true combination vaccine, containing both in one vial, does not yet exist on the market.
What This Means for Your Next Flu Season
For the foreseeable future, if you want protection against both influenza and COVID-19, you will need two separate shots. You can get them at the same visit with no safety penalty, and doing so is the most efficient approach. Ask your pharmacist or provider whether both are available when you schedule your fall appointment, since supply and eligibility windows vary by location and by which COVID booster is currently recommended.
If a combination vaccine does eventually receive approval, it would likely be offered alongside the standalone options rather than replacing them immediately. Some people may prefer the tried-and-true individual vaccines, while others will jump at the convenience of a single shot. Healthcare providers will need time to incorporate a new product into their workflows, and insurance coverage questions will need to be resolved. The transition, if it happens, will be gradual rather than abrupt.
For now, the bottom-line answer to the question is simple: the COVID vaccine is not in the flu shot. They are separate products. You can receive both at the same appointment safely, and a true single-shot combination is being tested but has not yet been approved. When in doubt, read the label on the vaccine information sheet your provider hands you before each injection. It will tell you exactly what you are receiving.